# XNW27011

Source: https://onco.cc/drugs/xnw27011/  
OnCo record `xnw27011` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

XNW27011 is an experimental antibody-drug conjugate from Astellas Pharma Global Development in phase 2 trials for pancreatic ductal adenocarcinoma, non-small-cell lung cancer and ovarian cancer, aimed at Claudin 18.2.

## Summary

XNW27011 is an antibody-drug conjugate developed by Astellas Pharma Global Development. Its target is Claudin 18.2 (the sponsor names Claudin 18.2 (CLDN18.2)). The sponsor states: XNW27011 is an antibody-drug conjugate targeting Claudin 18.2, a tight-junction transmembrane protein, carrying the topoisomerase I inhibitor payload YL0010014, given intravenously every three weeks. ClinicalTrials.gov describes the intervention as: Eligible patient(s) in each dose cohort will receive the assigned XNW27011 dose administration every 3 weeks (Q3W, cycle) until intolerable toxicity, progression of the disease without clinical benefit, or withdrawal of informed consent. An. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in pancreatic ductal adenocarcinoma, non-small-cell lung cancer, ovarian cancer, colorectal cancer and biliary tract cancer. The largest, NCT06792435, plans to enrol 240 participants with primary completion expected 2026-12-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: ADC
- Mechanism: XNW27011 is an antibody-drug conjugate targeting Claudin 18.2, a tight-junction transmembrane protein, carrying the topoisomerase I inhibitor payload YL0010014, given intravenously every three weeks.
- Payload: YL0010014 (topoisomerase I inhibitor), as stated in the registry record; DAR not stated

## Sources

- ClinicalTrials.gov: trials of XNW27011: https://clinicaltrials.gov/search?intr=XNW27011

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- targets: [Claudin 18.2](https://onco.cc/targets/cldn18-2/)
- companies: [Astellas](https://onco.cc/companies/astellas/)
- trials: [XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.](https://onco.cc/trials/nct06792435/)

---
JSON: https://onco.cc/api/v1/entities/xnw27011.json